Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15045-

  Pestina, Tamara I ^a   Hargrove, Phillip W ^a   Zhao, Huifen ^a   Mead, Paul E ^a   Smeltzer, Matthew P ^b   Weiss, Mitchell J ^a   Wilber, Andrew ^c   Persons, Derek A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD71 ANTIGEN; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HEMOSIDERIN; IRON; LENTIVIRUS VECTOR;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL LYSATE; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; ENGRAFTMENT; ERYTHROCYTE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENE THERAPY; GENE TRANSFER; GENETIC BACKGROUND; HEMATOPOIETIC STEM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; INSULATOR ELEMENT; KIDNEY CONCENTRATING CAPACITY; LEUKOCYTE COUNT; MOUSE; NEUTROPHIL COUNT; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROMOTER REGION; SICKLE CELL ANEMIA; SOUTHERN BLOTTING; SPLEEN WEIGHT; WHOLE BODY RADIATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ANIMAL CELL; CHICKEN; GLOBIN GENE; IMMUNOFLUORESCENCE; KIDNEY; KIDNEY FUNCTION; LEUKOCYTOSIS; LIVER; MOUSE MODEL; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; SPLEEN; STEM CELL GENE THERAPY;

EID: 84961657081     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.45     Document Type: Article

References (58)

1. 1 Sankaran, VG, Weiss, MJ, Anemia: progress in molecular mechanisms and therapies. Nat Med 21 (2015), 221–230.
2. 2 Bunn, HF, Pathogenesis and treatment of sickle cell disease. N Engl J Med 337 (1997), 762–769.
3. 3 Stamatoyannopoulos, G, Majerus, PW, Perlmutter, RM, Varmus, H, Molecular Basis of Blood Diseases, 2001, Saunders, Philadelphia 3rd edn.
4. 4 Voskaridou, E, Christoulas, D, Bilalis, A, Plata, E, Varvagiannis, K, Stamatopoulos, G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115 (2010), 2354–2363.
5. 5 Charache, S, Terrin, ML, Moore, RD, Dover, GJ, Barton, FB, Eckert, SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332 (1995), 1317–1322.
6. 6 Testa, U, Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 88 (2009), 505–528.
7. 7 Lobo, CL, Pinto, JF, Nascimento, EM, Moura, PG, Cardoso, GP, Hankins, JS, The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 161 (2013), 852–860.
8. 8 Steinberg, MH, Barton, F, Castro, O, Pegelow, CH, Ballas, SK, Kutlar, A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 (2003), 1645–1651.
9. 9 Steinberg, MH, McCarthy, WF, Castro, O, Ballas, SK, Armstrong, FD, Smith, W, et al., Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients’ Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 85 (2010), 403–408.
10. 10 Platt, OS, Brambilla, DJ, Rosse, WF, Milner, PF, Castro, O, Steinberg, MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330 (1994), 1639–1644.
11. 11 Bhatia, M, Walters, MC, Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant 41 (2008), 109–117.
12. 12 La Nasa, G, Caocci, G, Argiolu, F, Giardini, C, Locatelli, F, Vacca, A, et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant 36 (2005), 971–975.
13. 13 Gaziev, J, Marziali, M, Isgrò, A, Sodani, P, Paciaroni, K, Gallucci, C, et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood 122 (2013), 2751–2756.
14. 14 Jaing, TH, Chen, SH, Tsai, MH, Yang, CP, Hung, IJ, Tsay, PK, Transplantation of unrelated donor umbilical cord blood for nonmalignant diseases: a single institution's experience with 45 patients. Biol Blood Marrow Transplant 16 (2010), 102–107.
15. 15 Stamatoyannopoulos, G, Wood, WG, Papayannopoulou, T, Nute, PE, A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait. Blood 46 (1975), 683–692.
16. 16 Serjeant, GR, Serjeant, BE, Mason, K, Heterocellular hereditary persistence of fetal haemoglobin and homozygous sickle-cell disease. Lancet 1 (1977), 795–796.
17. 17 Labie, D, Pagnier, J, Lapoumeroulie, C, Rouabhi, F, Dunda-Belkhodja, O, Chardin, P, et al. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci USA 82 (1985), 2111–2114.
18. 18 Weatherall, DJ, The thalassemias. The Molecular Basis for Blood Disorders, 2001, Saunders, Philadelphia, 183–226 Stamatoyannopoulos G, Majerus P, Perlmutter R, Varmus HE (eds).
19. 19 Sankaran, VG, Xu, J, Orkin, SH, Advances in the understanding of haemoglobin switching. Br J Haematol 149 (2010), 181–194.
20. 20 Steinberg, MH, Chui, DH, Dover, GJ, Sebastiani, P, Alsultan, A, Fetal hemoglobin in sickle cell anemia: a glass half full?. Blood 123 (2014), 481–485.
21. 21 Ngo, DA, Aygun, B, Akinsheye, I, Hankins, JS, Bhan, I, Luo, HY, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol 156 (2012), 259–264.
22. 22 Villamizar, O, Chambers, CB, Wilber, A, Gene therapy for severe hemoglobin disorders. eLS, 2014 doi: 10.1002/9780470015902.a0025829.
23. 23 Emery, DW, Yannaki, E, Tubb, J, Nishino, T, Li, Q, Stamatoyannopoulos, G, Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100 (2002), 2012–2019.
24. 24 Levasseur, DN, Ryan, TM, Pawlik, KM, Townes, TM, Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102 (2003), 4312–4319.
25. 25 Pawliuk, R, Westerman, KA, Fabry, ME, Payen, E, Tighe, R, Bouhassira, EE, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294 (2001), 2368–2371.
26. 26 Pestina, TI, Hargrove, PW, Jay, D, Gray, JT, Boyd, KM, Persons, DA, Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 17 (2009), 245–252.
27. 27 Perumbeti, A, Higashimoto, T, Urbinati, F, Franco, R, Meiselman, HJ, Witte, D, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114 (2009), 1174–1185.
28. 28 Hsieh, MM, Fitzhugh, CD, Tisdale, JF, Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 118 (2011), 1197–1207.
29. 29 Hsieh, MM, Kang, EM, Fitzhugh, CD, Link, MB, Bolan, CD, Kurlander, R, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361 (2009), 2309–2317.
30. 30 Hsieh, MM, Fitzhugh, CD, Weitzel, RP, Link, ME, Coles, WA, Zhao, X, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 312 (2014), 48–56.
31. 31 Urbinati, F, Hargrove, PW, Geiger, S, Romero, Z, Wherley, J, Kaufman, ML, et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol 43 (2015), 346–351.
32. 32 Wilber, A, Hargrove, PW, Kim, YS, Riberdy, JM, Sankaran, VG, Papanikolaou, E, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 117 (2011), 2817–2826.
33. 33 Zheng, Y, Collins, SL, Lutz, MA, Allen, AN, Kole, TP, Zarek, PE, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 178 (2007), 2163–2170.
34. 34 Al-Salem, AH, Splenic complications of sickle cell anemia and the role of splenectomy. ISRN Hematol, 2011, 2011, 864257.
35. 35 Scheinman, JI, Sickle cell disease and the kidney. Nat Clin Pract Nephrol 5 (2009), 78–88.
36. 36 Pearson, HA, Gallagher, D, Chilcote, R, Sullivan, E, Wilimas, J, Espeland, M, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 76 (1985), 392–397.
37. 37 Nottage, KA, Ware, RE, Winter, B, Smeltzer, M, Wang, WC, Hankins, JS, et al. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Eur J Haematol 93 (2014), 377–383.
38. 38 Romero, Z, Urbinati, F, Geiger, S, Cooper, AR, Wherley, J, Kaufman, ML, et al. β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest 123 (2013), 3317–3330.
39. 39 Walters, MC, Patience, M, Leisenring, W, Eckman, JR, Scott, JP, Mentzer, WC, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 335 (1996), 369–376.
40. 40 Vermylen, C, Cornu, G, Ferster, A, Brichard, B, Ninane, J, Ferrant, A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 22 (1998), 1–6.
41. 41 Bernaudin, F, Socie, G, Kuentz, M, Chevret, S, Duval, M, Bertrand, Y, et al., SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (2007), 2749–2756.
42. 42 Powell, JD, Fitzhugh, C, Kang, EM, Hsieh, M, Schwartz, RH, Tisdale, JF, Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation 80 (2005), 1541–1545.
43. 43 Jäger, MD, Liu, JY, Timrott, KF, Popp, FC, Stoeltzing, O, Lang, SA, et al. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats. Exp Hematol 35 (2007), 164–170.
44. 44 Kean, LS, Adams, AB, Strobert, E, Hendrix, R, Gangappa, S, Jones, TR, et al. Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant 7 (2007), 320–335.
45. 45 Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
46. 46 Payen, E, Leboulch, P, Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2012 (2012), 276–283.
47. 47 Negre, O, Bartholomae, C, Beuzard, Y, Cavazzana, M, Christiansen, L, Courne, C, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Curr Gene Ther 15 (2015), 64–81.
48. 48 Thompson, AA, Rasko, JE, Hongeng, S, et al. Initial results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for β-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral βA-T87Q-globin vector (Lentiglobin BB305 drug product) [abstract]. Blood, 124, 2014, 549.
49. 49 Powars, DR, Weiss, JN, Chan, LS, Schroeder, WA, Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?. Blood 63 (1984), 921–926.
50. 50 Bunn, HF, Induction of fetal hemoglobin in sickle cell disease. Blood 93 (1999), 1787–1789.
51. 51 Stevens, MC, Hayes, RJ, Vaidya, S, Serjeant, GR, Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr 98 (1981), 37–41.
52. 52 Poillon, WN, Kim, BC, Rodgers, GP, Noguchi, CT, Schechter, AN, Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA 90 (1993), 5039–5043.
53. 53 Fehse, B, Kustikova, OS, Bubenheim, M, Baum, C, Pois(s)on–it's a question of dose. Gene Ther 11 (2004), 879–881.
54. 54 National Institutes of Health. Clinical Trials.gov https://clinicaltrials.gov/ct2/results?term=sickle+cell+anemia+AND+gene+therapy&recr=Open, Accessed 6 March 2015.
55. 55 Baldwin, K, Urbinati, F, Romero, Z, Campo-Fernandez, B, Kaufman, ML, Cooper, AR, et al. Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy. Stem Cells 33 (2015), 1532–1542.
56. 56 Hoban, MD, Cost, GJ, Mendel, MC, Romero, Z, Kaufman, ML, Joglekar, AV, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 125 (2015), 2597–2604.
57. 57 Hanawa, H, Kelly, PF, Nathwani, AC, Persons, DA, Vandergriff, JA, Hargrove, P, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5 (2002), 242–251.
58. 58 Persons, DA, Allay, ER, Sawai, N, Hargrove, PW, Brent, TP, Hanawa, H, et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102 (2003), 506–513.